Ask Warren

G2GBIO

456160 · KOSDAQ · ₩456160 · 지투지바이오

₩45,200▼ ₩4,500 (9.05%)End-of-day · Oct 26, 2026 · End-of-day prices.
Trade
Alert me
Price · 1Y −26.62%
Market cap
₩752B
Enterprise value
₩672B
P/E
—
P/B
5.4×
Dividend yield
0.0%
ROE
−10.8%
Net margin
−674.6%

Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.

52-week range−63.5% from the high

₩22,400Today: ₩44,200 – ₩52,200₩124,000

Returns

  • 1W+40.4%
  • 1M+41.0%
  • 3M+47.7%
  • 6M−44.7%
  • YTD−32.5%
  • 1Y−20.9%
Volume today
605,249
1.6× the 20-day average
Traded today
₩29B
Listed shares
16,629,426
EPS (12 months)
−₩899
Earnings yield −2.0%
SellBuy
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.

Upcoming dates

Full calendar →

🎁 Gift this stock

Send a friend ₩100,000 of paper money in this stock. They get it when they join.

XfWATGr/in@

Why is it moving?

−9.1% on Oct 26, 2026. Trading value 1.9× its normal.

G2GBIO shares rose sharply, and reports say the rise was driven by hopes of a collaboration with Novo. Two related Korean biotech stocks, Noul and FutureChem, also hit their daily upper price limit. The company also filed notice of an investor relations event.

AI summary of the news and filings linked. It can be wrong; check them.

Possible reasons, not certainties. Not financial advice.

Signals

62Warming up
  • BuzzRisingBuzz 62: heavy trading.
  • SentimentMixedNews: Mixed: a strong share price jump, but the Novo collaboration is only a hope in the reports and a routine IR event was filed. Community: 0 bullish, 0 bearish posts this week.
  • MomentumStrong40.8% over the last month; the price is above its 20-day average.
  • News impactSome16 news items and filings in two weeks; 0 rated high impact, 4 medium.

Signals describe activity, not recommendations. Not financial advice.

Leveraged ETF flows

Estimated leveraged-ETF rebalance on Oct 26: sell ₩511M at the close (3.0% of 20-day average trading value)

Sep 1Last 20 trading days (% of average trading value)Oct 26

On its 35 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 5.7% of trading value and pointed the same way 16 of 35 times.

  • 2× KODEX KOSDAQ150 Leverage −₩431M
  • -1× KODEX KOSDAQ150 Futures Inverse −₩36M
  • 2× TIGER KOSDAQ150 Leverage −₩32M
  • 2× RISE KOSDAQ150 Futures Leverage −₩9.2M

Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.

Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.

Estimate based on ETF size and daily moves; actual trades may differ.

ETFs holding this

All ETFs →

Held by 11 funds.

Estimated from the funds' index or underlying stock.

G2GBIO stock overview

G2GBIO (지투지바이오, KRX: 456160) is listed on KOSDAQ, in the Biotech & Pharma sector. The company is a Korean leader in long-acting drug microsphere technology, offering its proprietary InnoLAMP platform, which can carry synthetic drugs, peptides, antibodies and RNA therapeutics for sustained release after injection. Its shares closed at ₩45,200 on Oct 26, 2026, down 9.05% on the day, giving it a market value of ₩752B.

Key facts

Market cap
₩752B
Sector
Biotech & Pharma
Latest price change
−9.05%
As of
Oct 26, 2026
Main business
The company is a Korean leader in long-acting drug microsphere technology, offering its proprietary InnoLAMP platform, which can carry synthetic drugs, peptides, antibodies and RNA therapeutics for sustained release after injection.

Quick answers about G2GBIO

What does G2GBIO do?
The company is a Korean leader in long-acting drug microsphere technology, offering its proprietary InnoLAMP platform, which can carry synthetic drugs, peptides, antibodies and RNA therapeutics for sustained release after injection. Its revenue comes mainly from technology licensing, joint development and research services, and CDO/CDMO contracts with domestic and global pharmaceutical partners. Its lead pipeline includes candidates for diabetes/obesity, dementia and postoperative pain, and it operates production facilities in Cheongju, Korea.
What is the market cap of G2GBIO?
The market capitalisation of G2GBIO was ₩752B at the close on Oct 26, 2026.
Who are the largest shareholders of G2GBIO?
According to the latest official filings, the largest reported holders are Lee Hee-yong (22.90%, as of Aug 21, 2026); VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND (3.56%, as of Jul 31, 2026); Seol Eun-young (3.52%, as of May 21, 2026).
When is the next earnings report from G2GBIO?
Korean companies rarely announce results dates in advance. Based on when G2GBIO filed the same report in past years, its next 3q results is expected between Nov 13, 2026 and Nov 14, 2026.
Does the National Pension Service own G2GBIO?
Yes. The National Pension Service held 2.41% of G2GBIO shares as of Dec 31, 2025.

Company profile

The company is a Korean leader in long-acting drug microsphere technology, offering its proprietary InnoLAMP platform, which can carry synthetic drugs, peptides, antibodies and RNA therapeutics for sustained release after injection. Its revenue comes mainly from technology licensing, joint development and research services, and CDO/CDMO contracts with domestic and global pharmaceutical partners. Its lead pipeline includes candidates for diabetes/obesity, dementia and postoperative pain, and it operates production facilities in Cheongju, Korea.

Written by AI from the company's latest annual report.

Korean name
지투지바이오
Sector
Biotech & Pharma
Themes
Biotech (new drugs)Obesity drugs
CEO
이희용
Founded
Mar 2017
Listed
Aug 2025
Listed shares
16,629,426
Fiscal year ends
Month 12
Website
—

Similar companies

Recent news

Recent filings

See all

Titles in Korean until English translations are added.

Also known as: G2GBIO / 지투지바이오 / 456160 / KRX:456160

Source: KRX statistical information